Outlook Wealth Advisors LLC Buys 39 Shares of Eli Lilly and Company (NYSE:LLY)

Outlook Wealth Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 345 shares of the company’s stock after purchasing an additional 39 shares during the period. Outlook Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $266,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in LLY. ERn Financial LLC lifted its stake in shares of Eli Lilly and Company by 1.8% in the 4th quarter. ERn Financial LLC now owns 1,526 shares of the company’s stock valued at $1,178,000 after purchasing an additional 27 shares during the last quarter. BluePath Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 171.9% during the 4th quarter. BluePath Capital Management LLC now owns 1,580 shares of the company’s stock worth $1,260,000 after purchasing an additional 999 shares during the last quarter. Sawyer & Company Inc lifted its position in Eli Lilly and Company by 88.0% during the fourth quarter. Sawyer & Company Inc now owns 12,154 shares of the company’s stock valued at $9,383,000 after acquiring an additional 5,689 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in shares of Eli Lilly and Company by 0.9% in the 4th quarter. Pinnacle Bancorp Inc. now owns 5,269 shares of the company’s stock worth $4,068,000 after purchasing an additional 46 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 4.8% in the fourth quarter. Redhawk Wealth Advisors Inc. now owns 6,868 shares of the company’s stock worth $5,302,000 after acquiring an additional 313 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 1.6 %

Shares of LLY opened at $758.70 on Friday. The stock has a market cap of $720.25 billion, a PE ratio of 82.02, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52-week low of $612.70 and a 52-week high of $972.53. The firm’s fifty day moving average is $784.03 and its two-hundred day moving average is $856.70.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The firm’s revenue was up 20.4% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 13.14 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LLY. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Barclays cut their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Finally, Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.